Introduction
Cancer is associated with a high risk of thrombosis 1 . Among hematological malignancies, multiple myeloma(MM) has an especially high rate of both arterial and venous thrombotic events (VTE) 2 . Further, patients treated with the immunomodulatory drugs(IMiDs) thalidomide and lenalidomide experience a substantially elevated VTE risk(15-30%) 3 . In sharp contrast, MM patients receiving proteasome inhibitor bortezomib(BZ) have a VTE risk that is less than 4% 4, 5 .
Consistently, BZ treatment in hypertensive rat models decreases arterial thrombosis 6 . Although in vitro and ex vivo studies show that BZ inhibits platelet aggregation, the magnitude of this effect is insufficient to explain the profound decrease in VTE noted with BZ [7] [8] [9] . Consequently, alternative mechanisms are likely operative and account for the anti-thrombotic effects of BZ.
KLF2 is a member of the zinc finger family of transcription factors that is highly expressed in endothelial and hematopoietic cells [10] [11] [12] [13] . Studies in our laboratory identify KLF2 as a key regulator of endothelial [14] [15] [16] Further details are provided in Supplemental Methods.
Results and discussion:
Bortezomib prolongs time to occlusion in a carotid artery thrombosis assay. To determine if BZ confers an antithrombotic effect, C57BL/6J mice treated with a non-myelosuppressive dose of BZ (0.3mg/kg intraperitoneal thrice weekly for 2 weeks) were subjected to carotid artery thrombosis using the photochemical injury model 21 . Wild type mice treated with BZ demonstrated a significantly prolonged time to occlusive carotid artery thrombosis compared to saline treatment(40.8 ± 6 minutes vs. 29.4 ± 6 minutes, p = 0.006, n= 7 per group)( Figure 1A ).
There was no difference between WBC and platelet counts and RBC hemoglobin in saline and BZ-treated animals( Figure 1B) . Further, the antithrombotic effect was not associated with concomitant changes in the tail-bleeding( Figure 1C ) or in platelet activation assays( Figure 1D ).
Bortezomib induces KLF2.
A large body of work suggests that interaction between endothelial and hematopoietic cells(e.g. platelets and myeloid cells) regulates thrombosis 22 . As shown in Figure 2A , BZ induced KLF2 mRNA in both endothelial(HUVEC) and hematopoietic(RAW264.7
and MEG-01) cell lines. This induction is specific to KLF2 in the myeloid and megakaryocytic cell lines.Although KLF4 is concomitantly induced in endothelial cells(HUVEC), it was not as robust as the increase in KLF2 levels(Supplemental Figure 1) . Consistently, treatment of C57BL/6J mice with BZ induced KLF2 mRNA in peripheral white blood cells( Figure 2B ). To further understand how KLF2 levels are induced, we examined the effect of BZ on a KLF2
promoter luciferase construct and found that BZ induced KLF2 promoter activity(Supplemental Conversely, KLF2 knockout demonstrated a significant increase in iNOS levels in peritoneal macrophages and plasminogen activator inhibitor 1 (PAI-1) in endothelial cells. (Figure 2E ).
Our findings are the first in vivo studies to implicate a transcription factor, namely KLF2, as a key orchestrator of the thromboprotective effect observed with BZ. Previous in vitro studies 23, 24 . Given that KLF2 is known to confer potent anti-inflammatory effects and induce eNOS, it is possible that these observations are secondary to increased KLF2 levels as suggested by our studies.
An additional mechanism implicated in the anti-thrombotic effect of BZ is inhibition of platelet aggregation [7] [8] [9] . However, Avcu et al 7 described their observations as a mild platelet defect that was insufficient to explain the significant antithrombotic effect. Consistent with this view, we did not observe a significant effect on platelet activation following treatment with BZ. Hence, our findings that BZ's anti-thrombotic effects are abrogated in the absence of KLF2 implicates a more fundamental underlying mechanism. Interestingly, BZ treatment in hematopoietic cells (myeloid and megakaryocyte) specifically induces only one member of the KLF family, i.e.
KLF2.
Although both KLF2 and KLF4 are induced in the endothelium, the effect on KLF2 transcript levels is more robust. Since KLF4, a closely related member of the Kruppel family of transcription factors also has thromboprotective properties 25 , the demonstration that the antithrombotic effect of BZ is essentially lost in the absence of KLF2 compels us to postulate that in the context of BZ treatment, KLF2 must provide a more dominant antithrombotic effect, one that cannot be compensated for by endothelial induction of KLF4 that can occur with BZ treatment. We also demonstrate that KLF2 alters key thrombotic targets such as TM, PAI-1, and PAR-1. Although there is significant overlap in the number of downstream targets altered by both KLF2 and KLF4, it is likely that genes more critical to the thrombotic process are affected by KLF2 alone and reflect the dependency of BZ on this transcription factor for the antithrombotic benefit.
In summary, this study implicates the transcription factor KLF2 as a critical determinant of thrombosis. Our study also demonstrates that BZ induces KLF2 in both hematopoietic and
endothelial cells and provides in vivo genetic evidence that the antithrombotic benefit noted with BZ is KLF2-dependent. Hence, KLF2 may be a novel target amenable to pharmacological manipulation in the management of thrombosis. Further studies are being pursued to elucidate the relative contribution of each cell type in the thromboprotective effect and will provide useful insights in the molecular mechanisms and potential targets for amelioration of thrombosis.
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